Integral Diagnostics Ltd (IDX) - Net Assets

Latest as of June 2025: AU$693.94 Million AUD ≈ $491.01 Million USD

Based on the latest financial reports, Integral Diagnostics Ltd (IDX) has net assets worth AU$693.94 Million AUD (≈ $491.01 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$1.43 Billion ≈ $1.01 Billion USD) and total liabilities (AU$732.53 Million ≈ $518.31 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Integral Diagnostics Ltd (IDX) strategic asset index to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$693.94 Million
% of Total Assets	48.65%
Annual Growth Rate	53.96%
5-Year Change	172.41%
10-Year Change	726.91%
Growth Volatility	350.62

Integral Diagnostics Ltd - Net Assets Trend (2012–2025)

This chart illustrates how Integral Diagnostics Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Integral Diagnostics Ltd market cap and net worth.

Annual Net Assets for Integral Diagnostics Ltd (2012–2025)

The table below shows the annual net assets of Integral Diagnostics Ltd from 2012 to 2025. Also explore net asset growth rate of Integral Diagnostics Ltd to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-06-30	AU$693.94 Million ≈ $491.01 Million	+130.01%
2024-06-30	AU$301.71 Million ≈ $213.48 Million	-19.12%
2023-06-30	AU$373.05 Million ≈ $263.96 Million	+7.43%
2022-06-30	AU$347.24 Million ≈ $245.70 Million	+36.31%
2021-06-30	AU$254.74 Million ≈ $180.24 Million	+11.57%
2020-06-30	AU$228.33 Million ≈ $161.56 Million	+79.48%
2019-06-30	AU$127.22 Million ≈ $90.02 Million	+36.18%
2018-06-30	AU$93.42 Million ≈ $66.10 Million	+3.40%
2017-06-30	AU$90.35 Million ≈ $63.93 Million	+7.66%
2016-06-30	AU$83.92 Million ≈ $59.38 Million	+100.57%
2015-06-30	AU$41.84 Million ≈ $29.60 Million	+1340.31%
2014-06-30	AU$2.90 Million ≈ $2.06 Million	+14.31%
2013-06-30	AU$2.54 Million ≈ $1.80 Million	+0.01%
2012-06-30	AU$2.54 Million ≈ $1.80 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Integral Diagnostics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 371450.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component	Amount	Percentage
Common Stock	AU$735.40 Million	106.12%
Other Comprehensive Income	AU$-5.26 Million	-0.76%
Total Equity	AU$693.00 Million	100.00%

Integral Diagnostics Ltd Competitors by Market Cap

The table below lists competitors of Integral Diagnostics Ltd ranked by their market capitalization.

Company	Market Cap
Medikaloka Hermina PT JK:HEAL	$612.26 Million
Jinzai Food Group Co Ltd SHE:003000	$612.29 Million
ECOVE Environment Corp TWO:6803	$612.30 Million
PIMCO Access Income Fund NYSE:PAXS	$612.45 Million
Isgec Heavy Engineering Limited NSE:ISGEC	$611.98 Million
GeoPark Ltd NYSE:GPRK	$611.97 Million
Top Resource Conservation Engineering Co Ltd SHE:300332	$611.53 Million
Beijing Career International Co Ltd SHE:300662	$611.40 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Integral Diagnostics Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 301,707,000 to 693,000,000, a change of 391,293,000 (129.7%).
Net income of 4,673,000 contributed positively to equity growth.
Dividend payments of 15,457,000 reduced retained earnings.
Share repurchases of 563,000 reduced equity.
Other comprehensive income increased equity by 3,067,000.
Other factors increased equity by 399,573,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	AU$4.67 Million	+0.67%
Dividends Paid	AU$15.46 Million	-2.23%
Share Repurchases	AU$563.00K	-0.08%
Other Comprehensive Income	AU$3.07 Million	+0.44%
Other Changes	AU$399.57 Million	+57.66%
Total Change	AU$-	129.69%

Book Value vs Market Value Analysis

This analysis compares Integral Diagnostics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.04x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 67.02x to 1.04x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2013-06-30	AU$0.03	AU$2.32	x
2014-06-30	AU$0.04	AU$2.32	x
2015-06-30	AU$0.35	AU$2.32	x
2016-06-30	AU$0.60	AU$2.32	x
2017-06-30	AU$0.62	AU$2.32	x
2018-06-30	AU$0.64	AU$2.32	x
2019-06-30	AU$0.63	AU$2.32	x
2020-06-30	AU$1.13	AU$2.32	x
2021-06-30	AU$1.26	AU$2.32	x
2022-06-30	AU$1.64	AU$2.32	x
2023-06-30	AU$1.58	AU$2.32	x
2024-06-30	AU$1.28	AU$2.32	x
2025-06-30	AU$2.23	AU$2.32	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Integral Diagnostics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.67%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.75%
• Asset Turnover: 0.44x
• Equity Multiplier: 2.06x
Recent ROE (0.67%) is below the historical average (25.61%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	127.10%	100.00%	1.27x	1.00x	AU$2.98 Million
2014	117.86%	83.10%	0.50x	2.84x	AU$3.13 Million
2015	10.76%	2.98%	0.97x	3.73x	AU$316.00K
2016	13.57%	6.79%	0.93x	2.16x	AU$3.00 Million
2017	17.13%	8.61%	0.94x	2.11x	AU$6.44 Million
2018	16.14%	7.96%	0.97x	2.09x	AU$5.74 Million
2019	16.49%	9.03%	0.74x	2.47x	AU$8.26 Million
2020	10.09%	8.40%	0.47x	2.57x	AU$200.00K
2021	12.27%	8.96%	0.53x	2.57x	AU$5.79 Million
2022	4.21%	4.07%	0.46x	2.25x	AU$-20.12 Million
2023	6.71%	5.69%	0.52x	2.25x	AU$-12.26 Million
2024	-20.12%	-12.92%	0.63x	2.47x	AU$-90.87 Million
2025	0.67%	0.75%	0.44x	2.06x	AU$-64.63 Million

Industry Comparison

This section compares Integral Diagnostics Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

Industry: Diagnostics & Research
Average net assets among peers: $82,913,650
Average return on equity (ROE) among peers: -12.85%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Integral Diagnostics Ltd (IDX)	AU$693.94 Million	127.10%	1.06x	$612.18 Million
Australian Clinical Labs Ltd (ACL)	$232.56 Million	76.65%	1.70x	$360.33 Million
Bcal Diagnostics Ltd (BDX)	$8.59 Million	-74.52%	0.43x	$21.75 Million
Cryosite Ltd (CTE)	$1.45 Million	126.98%	12.60x	$40.41 Million
Genetic Signatures Ltd (GSS)	$13.40 Million	-24.28%	0.09x	$10.61 Million
Genetic Technologies Ltd (GTG)	$7.58 Million	-32.20%	0.17x	$4.01 Million
Healius Ltd (HLS)	$409.41 Million	13.90%	0.48x	$228.64 Million
Imagion Biosystems Ltd (IBX)	$2.97 Million	-115.44%	0.64x	$2.78 Million
Inoviq Ltd (IIQ)	$29.06 Million	-38.38%	0.15x	$17.43 Million
Microba Life Sciences Ltd (MAP)	$41.22 Million	-48.38%	0.41x	$22.84 Million

About Integral Diagnostics Ltd

AU:IDX Australia Diagnostics & Research

Market Cap

$612.18 Million

AU$865.19 Million AUD

Market Cap Rank

#11280 Global

#287 in Australia

Share Price

AU$2.32

Change (1 day)

-0.85%

52-Week Range

AU$1.94 - AU$2.93

All Time High

AU$5.00